We ground everything in science.
This means scientific expertise and in-depth, in-house medical and clinical experience.
Most of our Avant Healthcare medical team hold an advanced degree—PhD, MD, PharmD, or MPH—and possess both subject matter expertise and the ability to serve as effective strategic communication partners to you. This translates into strong scientific strategies, impactful communications, and relevant education for your DOLs/KOLs, advisors, and communities.
1 in 5 agency employees
is part of our medical/scientific staff
Have at least one advanced degree
Have two or more advanced degrees
Of our medical staff prefer dogs vs cats
THERAPEUTIC AREA SPOTLIGHT
Cultivating breakthrough success
We have worked in the immunology space for more than nine years, supporting multiple blockbuster products across more than 10 individual disease states. During this time, we have witnessed tremendous innovation within the field, with multiple disease states moving from a single modality to more than four separate classes of treatment options. We have served as a strategic partner for more than 15 new product/indication launches to provide patients with much-needed treatment options. As we look ahead, we can’t wait to see what the next nine years will bring.
Inflammatory Bowel Disease
Since 2014, we’ve had a front-row seat to witness the flood of innovation that has significantly expanded this landscape. From TNF inhibitors to the most recent approvals targeting S1P, JAK, and IL-23, we’ve supported multiple products across adult and pediatric Crohn’s disease and ulcerative colitis.
We have supported a number of products, including blockbuster innovations, withing the plaque psoriasis space. With each new development, we have helped our partners raise patient and HCP expectations on what is possible with therapy, above and beyond just PASI 75 and even PASI 90.
Through our experience across multiple classes of therapeutics, including biologics and small molecules, we’ve witnessed the move from focusing solely on tender and swollen joint counts to a treat-to-target approach. Remission is now the ultimate goal, with an increased focus on patient-centric measures, that include pain and fatigue.
Since 2014, we have supported new product and indication launches, including biologics and small molecules, in psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthropathy.
THERAPEUTIC AREA SPOTLIGHT
We entered the migraine space in 2017, and we’ve been in the thick of the exciting advancements ever since. Our support for multiple products, including launches, encompasses therapies for acute migraine relief, as well as migraine prevention. From differing mechanisms of action to different modes of administration, we have galvanized HCP adoption and advocacy across both neurology and primary care.
Since 1994, we have supported new indications for several antipsychotic products across a range of mental health conditions and neurodegenerative disorders. The emergence of these new therapies has significantly improved the lives of millions of patients living with disorders like schizophrenia, major depressive disorder, bipolar I disorder, and—with the most recent breakthroughs—treating patients with agitation associated with dementia due to Alzheimer’s disease.
For over a decade, we’ve been partners in the fight against Alzheimer’s disease. Within this space, we’ve supported the launch of diagnostic agents, as well as paradigm-changing, disease-modifying therapies. From disease state education to technical specialty trainings, this therapeutic area is one of our deep passions.
Supporting both in-market and investigational products, we’ve provided strategic partnership in the Parkinson’s disease space for many years. We have helped our clients navigate complex challenges around delivering effective treatments for Parkinson’s disease using novel delivery devices. Given the rapid advancements in therapy and modes of administration for Parkinson's disease, we are passionate in helping our clients address the large unmet need in this space to provide more tolerable and consistent relief for patients.
THERAPEUTIC AREA SPOTLIGHT
A key focus since 2011, our work in oncology started with just a single partnership. Today, it spans more than 25 unique product/indication combinations and counting. The evolution of our experience mirrors the unparalleled innovations we have witnessed and supported in the last decade, from chemotherapy to the advent of immuno-oncology, bispecific antibodies and T-cell engagers, and antibody-drug conjugates.
We leverage our deep expertise to help our partners navigate complex challenges across their solid tumor and hematologic oncology portfolios. Fluent in the nuances around accelerated approval and orphan drug status, we have partnered in 15-plus launches to date. Understanding oncologists’ passion and what concerns them every day, we facilitate robust medical conversations that advance scientific knowledge and patient care.
Our strategic partnership in hematologic oncology began in 2018. It has since grown to support multiple innovative therapies across a wide range of hematologic cancers, including AML, CLL, DLBCL, FL, and MCL, to name a few. We have worked hand-in-hand with our clients to fill the large unmet needs that exist within this field, supporting three accelerated approval launches within six months, with several more on the horizon as the landscape continues to evolve and more therapeutic options become available to patients in need.
Over a decade ago, we entered the lung cancer space with an indication expansion launch for a standard-of-care product, which we continued to support throughout its life cycle. Since then, our lung cancer portfolio has grown significantly to include a variety of products across lines of therapy and patient populations, including several new product launches and indication expansions. Whether it’s systemic chemotherapy or first-in-class precision oncology, we have become trusted strategic partners for our clients as they navigate the ever-evolving lung cancer treatment landscape.
We have been helping our clients navigate the dynamic HR+, HER2- landscape since CDK inhibitors first became standard of care in metastatic disease. We provided strategic support in bringing a major advancement in care to market in the adjuvant setting and now look forward to the next wave of innovation in oral SERDs. Whether it’s oncologists or the allied care team, overall survival, or managing side effects to preserve quality of life, we are experts in meeting your audience where they are and covering the topics that are most important to them and your brand.
We are experts on colorectal cancer, thanks to our many years serving clients in the gastrointestinal cancer space. Over the course of a decade, we have provided support ranging from mid-life cycle strategy and content development to full launch executions for a variety of products. We have seen and been a part of major innovations in this treatment landscape, including a recent tumor agnostic launch of a precision therapy, which fills an unmet need for certain patients with metastatic colorectal cancer. These breakthroughs and the positive impact they have on patients are what drive us.
Our Medical Leaders
“Unbelievable follow-through, poise, anticipation of needs, and big-picture thinking.”— VP, Global Medical Affairs, Gene Therapy/Device Biotech
“Avant is the best agency I have worked with in my 20 years in the business.”— VP, Global Medical Affairs, Gene Therapy/Device Biotech
“Avant has a unique ability to take complex, highly scientific strategic messages and weave them into a compelling story.”— Director, HCP Marketing, Cardiology, top pharma company
“Avant creates a story that not only meets the audience’s educational needs, but also gives physicians something they can rally around and take back to their practices.”— Director, HCP Marketing, Cardiology, top pharma company
“I can’t help but rave about the amazing job you have been doing for our brand.”— Senior Marketing Manager, Oncology, top pharma company
“Avant not only plays well in the sandbox—they are the sandbox.”— Marketing Director, top-10 pharma company
“The Avant team has made significant contributions to our business. It’s a great partnership.”— Senior VP, US Commercial Operations, top-3 pharma company
“Avant is strategic, has strong execution, and brings innovation.”— Brand Director
“The Avant team has made many significant contributions to our business.”— Senior VP, top-5 pharma company
“Avant is a trusted and knowledgeable partner. I would recommend them any day to a colleague.”— Marketer, top-5 pharma company
“Avant listens and creates an atmosphere of ‘anything is possible.’”— Marketer, top-5 pharma company
“Avant account teams are some of the best I’ve worked with.”— Marketer, top-5 pharma company
“The Avant team has done an exceptional job improving our strategic approach to Thought Leader engagement, resulting in higher ROI.”— Senior Product Manager
“Avant account teams are some of the best I’ve worked with.”— Marketer, top-5 pharma company
“This all-star group works hard, thinks strategically, collaborates well, and most importantly, has shown us time after time what good actually looks like.”— Associate Marketing Director
“97% of clients would recommend Avant Healthcare”— Voice of the Customer survey
“98% of clients would do business with Avant Healthcare again”— Voice of the Customer survey
THERAPEUTIC AREAS OF EXPERTISE
Our scientific experience runs deep
Like the healthcare space we’ve been a part of since 1994, our expertise is ever-evolving, as scientific innovations bring new opportunities to expand the depth and breadth of our support to our clients and their patients.
Across the dermatological landscape, we’ve helped our clients bring powerful therapeutic solutions to market in the following areas:
Plaque psoriasis (PsO) • Psoriatic arthritis (PsA) • Atopic dermatitis (AD) • Hidradenitis suppurativa (HS)
As our clients seek to improve the lives of patients, we’ve been relentless in supporting their efforts around the following incapacitating conditions:
Rheumatoid arthritis (RA) • Psoriatic arthritis (PsA) • Ankylosing spondylitis (AS) • Nonradiographic axial spondyloarthropathy (NR-axSpA) • Juvenile idiopathic arthritis (JIA)
We have extensive experience across psychiatry, neurodegeneration, and pain, including:
Agitation associated with dementia (AAD) • Bipolar I disorder (BP-I) • General anxiety disorder (GAD) • Major depressive disorder (MDD) • Schizophrenia (SZ) • Post-traumatic stress disorder (PTSD) • Alzheimer’s disease • Huntington’s disease • Parkinson’s disease (PD) • Migraine • Cluster headache • Chronic pain syndromes
Bringing the major advances in this field into view, we’ve supported our clients as they’ve introduced innovative treatment solutions for:
Uveitis • Presbyopia • Open angle glaucoma (OAG) • Age-related macular degeneration (AMD)
We’ve been proud to assist our clients in their quest to bring innovative therapeutic options to patients with:
Adult and pediatric Crohn’s disease (CD) and ulcerative colitis (UC) • Irritable bowel syndrome (IBS) • Chronic idiopathic constipation • Eosinophilic esophagitis (EE) • Exocrine pancreatic insufficiency (EPI) • Postoperative nausea and vomiting
Helping clients bring life-altering treatment options to patients with significantly burdensome, often rare/orphan diseases, we’ve provided support in the areas of:
Sickle cell anemia • Thalassemia • Hemophilia
Our support for breakthrough therapies has helped our clients advance the fight against the following widespread viral infections:
COVID-19 • Human immunodeficiency virus (HIV) • Hepatitis B • Hepatitis C • Human papilloma virus (HPV)
Through experience, we’ve built a strong expertise in developing compelling medical education programs for:
Autosomal dominant polycystic kidney disease (ADPKD)
Solid Tumor Oncology
As a witness to unprecedented breakthroughs in oncology, we’ve supported the advent of personalized medicine for patients with:
Head and neck cancer • Metastatic uveal melanoma • Breast cancer • Non-small cell lung cancer • Gastroesophageal adenocarcinoma • Gastric cancer • Hepatocellular carcinoma • Colorectal cancer • Prostate cancer • Bladder cancer
We’ve remained laser-focused on helping our clients bring the benefits of precision medicine to life, as they have introduced biomarker-targeted therapies and other breakthrough treatments to many patients with the following blood cancers:
Chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) • Acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) • Multiple myeloma (MM) • Myelofibrosis (MF) • Diffuse large B-cell lymphoma (DLBCL) • Mantle cell lymphoma (MCL) • Follicular lymphoma (FL)
Supporting important advances in women’s health, we have developed medical education initiatives that have addressed the following painful, often debilitating conditions:
Fibroids • Endometriosis • Preterm labor • Preeclampsia • Dyspareunia • Hypoactive sexual desire dysfunction (HSDD)
We’ve partnered with our clients to bring clinically meaningful treatment options to patients with:
Chronic obstructive pulmonary disease (COPD) • Cystic fibrosis (CF)
We’ve shared the same determination as our clients to bring meaningful relief to patients in the following areas:
Osteoarthritis • Chronic lower back pain (CLBP) • Diabetic peripheral neuropathic pain (DPNP) • Fibromyalgia (FM) • Anesthesiology
Providing food for thought and meaningful discussion, we’ve successfully supported our clients in the following areas:
Supportive care • Infant/pediatric nutrition • Food allergies
We’ve kept our finger on the pulse of significant innovations for the treatment of the following cardiovascular disorders:
Heart failure with preserved ejection fraction (HFpEF) • Heart failure with reduced ejection fraction (HFrEF) • Atrial fibrillation (Afib)
We have deep experience helping our clients introduce novel therapies for the treatment of the following chronic conditions:
Diabetes • Osteoporosis
We’ve become specialists in supporting our clients’ solutions for the treatment of the following sensitive conditions:
Benign prostatic hyperplasia (BPH) • Erectile dysfunction (ED) • Nocturia
Within the aesthetics space, we’ve been proud to support clients as they provide advanced solutions to patients seeking:
Facial and buttock aesthetics • Plastic surgery
Our Medical Advisory Board
Invaluable insights from industry-leading HCPs
Established in 2011, our Medical Advisory Board helps strengthen our network of academic and KOL partnerships while reinforcing our commitment to housing a medical education center of excellence. Permanent board members offer our staff the ability to consult periodically with regional specialists who provide us with invaluable clinical insights. In turn, the board helps to further solidify our position as an authoritative presence and thought leader in medical strategy and communications.